Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote

Dow Jones

06/17

By Grace Yoon

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.

Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.

"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease," Chief Executive Eric Dube said.

Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.

Write to Grace Yoon at grace.yoon@wsj.com.

- -

(END) Dow Jones Newswires

June 16, 2026 17:13 ET (21:13 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2644798730"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644798730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644798730?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644798730","market":"sh","top_or_hot":-1,"title":"Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-17 05:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644798730","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644798730","pubTimestamp":1781644380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.\"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said.Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","TVTX":"Travere Therapeutics, Inc.","BK4007":"制药","BK4539":"次新股","BK4139":"生物科技","FFTY":"Innovator IBD 50 ETF"},"translate_title":"Travere Therapeutics任命Inrig为新任研究主管，接替Rote","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9,"FFTY":1.5,"LENZ":1.5},"content_text":"By Grace Yoon \n\n\n  Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. \n\n\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n\n\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n\n\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com. \n\n\n- - \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 17:13 ET (21:13 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}